Cargando…
M125. DISEASE PREVALENCE, COMORBID CONDITIONS, AND MEDICATION UTILIZATION AMONG PATIENTS WITH SCHIZOPHRENIA IN THE UNITED STATES
BACKGROUND: The comorbid medical and psychiatric burden for individuals with schizophrenia in the United States is substantial compared with the general population. This study sourced the IBM® MarketScan® Research Databases to examine disease prevalence, comorbid conditions, and drug treatments in a...
Autores principales: | Roy, Brittany, Li, Jianheng, Lally, Cathy, Shah, Ankitaben, Bloomgren, Gary, Wenten, Made |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234763/ http://dx.doi.org/10.1093/schbul/sbaa030.437 |
Ejemplares similares
-
Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data
por: Bloomgren, Gary, et al.
Publicado: (2012) -
M215. FACTORS ASSOCIATED WITH CLOZAPINE RESPONSE AND RESISTANCE IN SCHIZOPHRENIA
por: Lee, Jimmy, et al.
Publicado: (2020) -
Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study
por: Friend, Susan, et al.
Publicado: (2016) -
M222. SURVEY RESULTS FROM TURKEY: KNOWLEDGE ABOUT SCHIZOPHRENIA, PUBLIC STIGMA AND DISCRIMINATION BECAUSE OF SCHIZOPHRENIA
por: Haldun, Soygur, et al.
Publicado: (2020) -
M73. DRIVING ABILITIES IN PATIENTS WITH SCHIZOPHRENIA
por: Pardeller, Silvia, et al.
Publicado: (2020)